Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind placebo-controlled Phase IIb trial evaluating evaluate the safety and tolerability of RJx-01 in COPD-related sarcopenia

Next Previous
Trial Profile

A double-blind placebo-controlled Phase IIb trial evaluating evaluate the safety and tolerability of RJx-01 in COPD-related sarcopenia

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 19 May 2025 According to a Rejuvenate Biomed media release, the first patient has been dosed
  • 19 May 2025 Status changed from planning to recruiting.
  • 28 Oct 2024 According to a Rejuvenate Biomed media release, Rejuvenate Biomed, this study will be led by Dr Neil Greening and Dr Hamish McCauley from the NIHR Leicester BRC at University Hospitals of Leicester NHS Trust.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top